Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study
l
Lost to follow up (L2FU) patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research.
L2FU, a company specializing in helping clinical trial sites and biopharma companies to locate, contact and collect data from patients deemed 'Lost to Follow-Up', is building a portfolio of successes and an industry reputation for its quality work. The L2FU team proudly reports its latest successful recovery of 100% of a recent study's lost clinical trial patients. This was achieved in only one month to meet a truncated timeline. The client, a leading integrated managed care organization, with operations in a number of major states across the US and nearly 10 million patient members, required the information rapidly.L2FU is part of MediciGlobal.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
